MYC and colorectal carcinoma: Additionally, utilizing compounds derived from natural products to target specific oncogenes such as c-Myc, CCR4-NOT transcription complex subunit 2 (CNOT2) and MID1-interacting protein 1 (MID1IP1) have been proposed as an innovative treatment for various cancers, particularly CRC [5,6,7].